D W Fry - JoVE Visualize

Showing results (51-60 of 82) with videos related to

Pageof 9

Sort By:

Journal of Medicinal Chemistry|January 20, 2000

Tyrosine kinase inhibitors. 16. 6,5,6-tricyclic benzothieno[3, 2-d]pyrimidines and pyrimido[5,4-b-] and -[4,5-b]ĭndoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinaseH D Showalter, A J Bridges, H Zhou, et al.

Anti-Cancer Drug Design|April 1, 1986

Design, biochemical pharmacology, electrochemistry and tumour biology of anti-tumour anthrapyrazolesH D Showalter, D W Fry, W R Leopold, et al.

Advances in Enzyme Regulation|January 1, 1989

Biochemical pharmacology and antitumor properties of 4-amino-8-[beta-D-ribofuranosylamino]pyrimido-[5,4-d]pyrimidineR C Jackson, T J Boritzki, P D Cook, et al.

Advances in Enzyme Regulation|January 1, 1985

The biochemical pharmacology of CI-920, a structurally novel antibiotic with antileukemic activityR C Jackson, D W Fry, T J Boritzki, et al.

Investigational New Drugs|January 1, 1985

Dezaguanine mesylate: a new antipurine antimetaboliteW R Leopold, D W Fry, T J Boritzki, et al.

Journal of Medicinal Chemistry|June 24, 1994

Tyrosine kinase inhibitors. 3. Structure-activity relationships for inhibition of protein tyrosine kinases by nuclear-substituted derivatives of 2,2'-dithiobis(1-methyl-N-phenyl-1H-indole-3-carboxamide)G W Rewcastle, B D Palmer, E M Dobrusin, et al.

Journal of Medicinal Chemistry|May 9, 1997

Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of bindingB D Palmer, S Trumpp-Kallmeyer, D W Fry, et al.

Journal of Medicinal Chemistry|September 1, 1995

Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptorG W Rewcastle, W A Denny, A J Bridges, et al.

The Journal of Biological Chemistry|June 11, 1998

Role of tyrosine kinase activity of epidermal growth factor receptor in the lysophosphatidic acid-stimulated mitogen-activated protein kinase pathwayJ M Cunnick, J F Dorsey, T Standley, et al.

Journal of Medicinal Chemistry|August 20, 1993

Tyrosine kinase inhibitors. 1. Structure-activity relationships for inhibition of epidermal growth factor receptor tyrosine kinase activity by 2,3-dihydro-2-thioxo-1H-indole-3-alkanoic acids and 2,2'-dithiobis(1H-indole-3-alkanoic acids)A M Thompson, G W Rewcastle, M Tercel, et al.

Pageof 9

Showing results (51-60 of 82) with videos related to

Sort By:

Pageof 9

Journal of Medicinal Chemistry|January 20, 2000

Tyrosine kinase inhibitors. 16. 6,5,6-tricyclic benzothieno[3, 2-d]pyrimidines and pyrimido[5,4-b-] and -[4,5-b]ĭndoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinaseH D Showalter, A J Bridges, H Zhou, et al.

Anti-Cancer Drug Design|April 1, 1986

Design, biochemical pharmacology, electrochemistry and tumour biology of anti-tumour anthrapyrazolesH D Showalter, D W Fry, W R Leopold, et al.

Advances in Enzyme Regulation|January 1, 1989

Biochemical pharmacology and antitumor properties of 4-amino-8-[beta-D-ribofuranosylamino]pyrimido-[5,4-d]pyrimidineR C Jackson, T J Boritzki, P D Cook, et al.

Advances in Enzyme Regulation|January 1, 1985

The biochemical pharmacology of CI-920, a structurally novel antibiotic with antileukemic activityR C Jackson, D W Fry, T J Boritzki, et al.

Investigational New Drugs|January 1, 1985

Dezaguanine mesylate: a new antipurine antimetaboliteW R Leopold, D W Fry, T J Boritzki, et al.

Journal of Medicinal Chemistry|June 24, 1994

Tyrosine kinase inhibitors. 3. Structure-activity relationships for inhibition of protein tyrosine kinases by nuclear-substituted derivatives of 2,2'-dithiobis(1-methyl-N-phenyl-1H-indole-3-carboxamide)G W Rewcastle, B D Palmer, E M Dobrusin, et al.

Journal of Medicinal Chemistry|May 9, 1997

Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of bindingB D Palmer, S Trumpp-Kallmeyer, D W Fry, et al.

Journal of Medicinal Chemistry|September 1, 1995

Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptorG W Rewcastle, W A Denny, A J Bridges, et al.

The Journal of Biological Chemistry|June 11, 1998

Role of tyrosine kinase activity of epidermal growth factor receptor in the lysophosphatidic acid-stimulated mitogen-activated protein kinase pathwayJ M Cunnick, J F Dorsey, T Standley, et al.

Journal of Medicinal Chemistry|August 20, 1993

Tyrosine kinase inhibitors. 1. Structure-activity relationships for inhibition of epidermal growth factor receptor tyrosine kinase activity by 2,3-dihydro-2-thioxo-1H-indole-3-alkanoic acids and 2,2'-dithiobis(1H-indole-3-alkanoic acids)A M Thompson, G W Rewcastle, M Tercel, et al.

Pageof 9